Related Experiment Videos

Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke

Sverre E Kjeldsen1, Paulette A Lyle, Jorge R Kizer

  • 1Department of Cardiology, Ullevaal University Hospital, N-0407 Oslo, Norway. s.e.kjeldsen@medisin.uio.no

Vascular Health and Risk Management
|August 21, 2007
PubMed

Insights

Fixed-dose losartan/hydrochlorothiazide (HCTZ) is effective for initial hypertension treatment. This combination therapy may reduce stroke risk and improve patient compliance.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Hypertension management requires effective and tolerable antihypertensive therapies.
  • Fixed-dose combinations offer convenience and may improve patient adherence.
  • Hydrochlorothiazide (HCTZ) can activate the renin-angiotensin-aldosterone system, potentially enhancing the effects of angiotensin II receptor blockers.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of fixed-dose losartan/hydrochlorothiazide (HCTZ) combination therapy for hypertension.
  • To assess the potential benefits of this combination in reducing stroke risk.
  • To explore its utility as an initial treatment option for patients with significant blood pressure elevation.

Main Methods:

  • Review of clinical data and studies, including the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
  • Analysis of the pharmacological interactions between losartan and HCTZ.
  • Assessment of adverse effect profiles and potential mitigation by combination therapy.

Main Results:

  • Losartan/HCTZ combination therapy demonstrates efficacy in lowering blood pressure.
  • The combination may offset certain adverse effects of HCTZ, such as increased risk for new-onset diabetes mellitus.
  • The LIFE study showed a 25% risk reduction for stroke with losartan-based treatment.

Conclusions:

  • Fixed-dose losartan/HCTZ is a logical choice for antihypertensive treatment, including initial therapy.
  • The combination's efficacy, tolerability, and convenience can enhance patient compliance.
  • This therapy may significantly lower the risk of stroke in hypertensive patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...